Ischemic heart diseases: Current treatments and future

Donghoon Choi, Ki Chul Hwang, Kuen Yong Lee, Yong Hee Kim

Research output: Contribution to journalReview article

45 Citations (Scopus)

Abstract

Ischemic heart disease is a rapidly increasing common cause of death in the world. This disease is the insufficient status of oxygen within the cardiac muscles due to an imbalance between oxygen supply and demand, and a cardiac disease that occurs as a result of coronary artery stenosis. Conventional surgery-based therapy for the treatment of ischemic heart diseases has been advanced with biopharmaceutical-based therapy, such as protein, gene and cell therapy. The conventional medical therapy focuses on the use of drug eluting stents, coronary-artery bypass-graft surgery and anti-thrombosis. Biopharmaceutical-based therapies including recombinant protein therapy, gene therapy and cell transplantation are recognized as promising approaches in inducing neovascularization and improving collateral blood flow in the ischemic heart. This review explores the current status and future of the treatment of ischemic heart diseases with conventional medical therapy, biopharmaceutical-based therapy focused on the proteins and polymeric hydrogels for delivery of therapeutic proteins.

Original languageEnglish
Pages (from-to)194-202
Number of pages9
JournalJournal of Controlled Release
Volume140
Issue number3
DOIs
Publication statusPublished - 2009 Dec 16

Fingerprint

Myocardial Ischemia
Therapeutics
Genetic Therapy
Oxygen
Proteins
Hydrogels
Drug-Eluting Stents
Coronary Stenosis
Cell Transplantation
Cell- and Tissue-Based Therapy
Recombinant Proteins
Coronary Artery Bypass
Cause of Death
Heart Diseases
Myocardium
Thrombosis
Transplants

All Science Journal Classification (ASJC) codes

  • Pharmaceutical Science

Cite this

Choi, Donghoon ; Hwang, Ki Chul ; Lee, Kuen Yong ; Kim, Yong Hee. / Ischemic heart diseases : Current treatments and future. In: Journal of Controlled Release. 2009 ; Vol. 140, No. 3. pp. 194-202.
@article{de0b65ddd8ad4cf1bde852c357584efd,
title = "Ischemic heart diseases: Current treatments and future",
abstract = "Ischemic heart disease is a rapidly increasing common cause of death in the world. This disease is the insufficient status of oxygen within the cardiac muscles due to an imbalance between oxygen supply and demand, and a cardiac disease that occurs as a result of coronary artery stenosis. Conventional surgery-based therapy for the treatment of ischemic heart diseases has been advanced with biopharmaceutical-based therapy, such as protein, gene and cell therapy. The conventional medical therapy focuses on the use of drug eluting stents, coronary-artery bypass-graft surgery and anti-thrombosis. Biopharmaceutical-based therapies including recombinant protein therapy, gene therapy and cell transplantation are recognized as promising approaches in inducing neovascularization and improving collateral blood flow in the ischemic heart. This review explores the current status and future of the treatment of ischemic heart diseases with conventional medical therapy, biopharmaceutical-based therapy focused on the proteins and polymeric hydrogels for delivery of therapeutic proteins.",
author = "Donghoon Choi and Hwang, {Ki Chul} and Lee, {Kuen Yong} and Kim, {Yong Hee}",
year = "2009",
month = "12",
day = "16",
doi = "10.1016/j.jconrel.2009.06.016",
language = "English",
volume = "140",
pages = "194--202",
journal = "Journal of Controlled Release",
issn = "0168-3659",
publisher = "Elsevier",
number = "3",

}

Ischemic heart diseases : Current treatments and future. / Choi, Donghoon; Hwang, Ki Chul; Lee, Kuen Yong; Kim, Yong Hee.

In: Journal of Controlled Release, Vol. 140, No. 3, 16.12.2009, p. 194-202.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Ischemic heart diseases

T2 - Current treatments and future

AU - Choi, Donghoon

AU - Hwang, Ki Chul

AU - Lee, Kuen Yong

AU - Kim, Yong Hee

PY - 2009/12/16

Y1 - 2009/12/16

N2 - Ischemic heart disease is a rapidly increasing common cause of death in the world. This disease is the insufficient status of oxygen within the cardiac muscles due to an imbalance between oxygen supply and demand, and a cardiac disease that occurs as a result of coronary artery stenosis. Conventional surgery-based therapy for the treatment of ischemic heart diseases has been advanced with biopharmaceutical-based therapy, such as protein, gene and cell therapy. The conventional medical therapy focuses on the use of drug eluting stents, coronary-artery bypass-graft surgery and anti-thrombosis. Biopharmaceutical-based therapies including recombinant protein therapy, gene therapy and cell transplantation are recognized as promising approaches in inducing neovascularization and improving collateral blood flow in the ischemic heart. This review explores the current status and future of the treatment of ischemic heart diseases with conventional medical therapy, biopharmaceutical-based therapy focused on the proteins and polymeric hydrogels for delivery of therapeutic proteins.

AB - Ischemic heart disease is a rapidly increasing common cause of death in the world. This disease is the insufficient status of oxygen within the cardiac muscles due to an imbalance between oxygen supply and demand, and a cardiac disease that occurs as a result of coronary artery stenosis. Conventional surgery-based therapy for the treatment of ischemic heart diseases has been advanced with biopharmaceutical-based therapy, such as protein, gene and cell therapy. The conventional medical therapy focuses on the use of drug eluting stents, coronary-artery bypass-graft surgery and anti-thrombosis. Biopharmaceutical-based therapies including recombinant protein therapy, gene therapy and cell transplantation are recognized as promising approaches in inducing neovascularization and improving collateral blood flow in the ischemic heart. This review explores the current status and future of the treatment of ischemic heart diseases with conventional medical therapy, biopharmaceutical-based therapy focused on the proteins and polymeric hydrogels for delivery of therapeutic proteins.

UR - http://www.scopus.com/inward/record.url?scp=70450278838&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70450278838&partnerID=8YFLogxK

U2 - 10.1016/j.jconrel.2009.06.016

DO - 10.1016/j.jconrel.2009.06.016

M3 - Review article

C2 - 19563848

AN - SCOPUS:70450278838

VL - 140

SP - 194

EP - 202

JO - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

IS - 3

ER -